https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52222 Thu 05 Oct 2023 10:30:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27000 50. A Cox multivariate regression model for LFS retained both B-other ALL subtype (hazard ratio 4·1, P = 0·0062) and MRD persistence post-HSCT (hazard ratio 3·9, P = 0·0070) as independent adverse prognostic variables. Persistent MRD could be used to direct post-HSCT therapy.]]> Sat 24 Mar 2018 07:25:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47275 Mon 27 Mar 2023 13:35:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46592 n = 33). SNP-microarray analysis identified additional aberrations in 97% of patients (32/33) compared to conventional techniques. This changed the genomic risk category of 24% (8/33) of patients. Additionally, 27% (9/33) of patients exhibited a ‘hyperdiploid’ genome, which is generally associated with a good genomic risk and favourable outcomes. An enrichment of IKZF1 deletions was observed with one third of the cohort affected. Our findings suggest the current classification system could be improved and highlights the need to use more sensitive techniques such as SNP-microarray for cytogenomic risk stratification in B-ALL.]]> Fri 25 Nov 2022 15:04:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44512 Fri 14 Oct 2022 09:11:36 AEDT ]]>